Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

114.32 +0.65 (+0.57%)
Streaming Delayed Price Updated: 3:23 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,808,680
Open 113.66
Bid (Size) 114.32 (2)
Ask (Size) 114.33 (2)
Prev. Close 113.67
Today's Range 113.31 - 114.60
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years. 
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
+0.95%
+0.95%
1 Month
-9.10%
-9.10%
3 Month
-12.73%
-12.73%
6 Month
-10.25%
-10.25%
1 Year
+4.27%
+4.27%

More News

Read More
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
Via InvestorPlace
Uncovering Dividend Opportunities with NYSE:MRK.
Via Chartmill
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Via Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Via Benzinga
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
The 3 Best Biotech Stocks to Buy in August 2024
Via InvestorPlace
NYSE:MRK is an undervalued gem with solid fundamentals.
Via Chartmill
Palantir’s AI Evolution: Strategic Shift Or Marketing Ploy?
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
From Daiichi Sankyo
Via Business Wire
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.